Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma
Abstract Neuroinflammation is a significant contributor to the pathology of glaucoma. Targeting key-mediators in this process is a realistic option to slow disease progression. Galectin-3 is a β-galactoside binding lectin that has been associated with inflammation in both systemic and central nervou...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Molecular Brain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13041-024-01160-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850163419742732288 |
|---|---|
| author | Anne Rombaut Rune Brautaset Pete A. Williams James R. Tribble |
| author_facet | Anne Rombaut Rune Brautaset Pete A. Williams James R. Tribble |
| author_sort | Anne Rombaut |
| collection | DOAJ |
| description | Abstract Neuroinflammation is a significant contributor to the pathology of glaucoma. Targeting key-mediators in this process is a realistic option to slow disease progression. Galectin-3 is a β-galactoside binding lectin that has been associated with inflammation in both systemic and central nervous system diseases. Elevated Galectin-3 has recently been detected in multiple animal models of glaucoma and inhibiting Galectin-3 using an intravitreal injection of TD139 (a Galectin-3 small molecule inhibitor) is neuroprotective. We queried whether this neuroprotective effect was translatable to another animal model and species. TD139 was intravitreally injected, in a rat ocular hypertensive model of glaucoma, 3 days after the induction of ocular hypertension (at peak intraocular pressure). Retinal ganglion cell survival and glial morphological markers were quantified. The degeneration of retinal ganglion cells was prevented by TD139 injection, but gross glial markers remained unaffected. These data confirm that the intravitreal injection of TD139 is neuroprotective in a rat ocular hypertensive model of glaucoma, while suggesting that the inhibition of Galectin-3 is not sufficient to alter the gross inflammatory outcome. |
| format | Article |
| id | doaj-art-4e5b23d2a1a04099a223a787e8b2bf3a |
| institution | OA Journals |
| issn | 1756-6606 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Brain |
| spelling | doaj-art-4e5b23d2a1a04099a223a787e8b2bf3a2025-08-20T02:22:16ZengBMCMolecular Brain1756-66062024-11-011711410.1186/s13041-024-01160-zIntravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucomaAnne Rombaut0Rune Brautaset1Pete A. Williams2James R. Tribble3Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska InstitutetDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska InstitutetDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska InstitutetDepartment of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska InstitutetAbstract Neuroinflammation is a significant contributor to the pathology of glaucoma. Targeting key-mediators in this process is a realistic option to slow disease progression. Galectin-3 is a β-galactoside binding lectin that has been associated with inflammation in both systemic and central nervous system diseases. Elevated Galectin-3 has recently been detected in multiple animal models of glaucoma and inhibiting Galectin-3 using an intravitreal injection of TD139 (a Galectin-3 small molecule inhibitor) is neuroprotective. We queried whether this neuroprotective effect was translatable to another animal model and species. TD139 was intravitreally injected, in a rat ocular hypertensive model of glaucoma, 3 days after the induction of ocular hypertension (at peak intraocular pressure). Retinal ganglion cell survival and glial morphological markers were quantified. The degeneration of retinal ganglion cells was prevented by TD139 injection, but gross glial markers remained unaffected. These data confirm that the intravitreal injection of TD139 is neuroprotective in a rat ocular hypertensive model of glaucoma, while suggesting that the inhibition of Galectin-3 is not sufficient to alter the gross inflammatory outcome.https://doi.org/10.1186/s13041-024-01160-zGalectin-3TD139NeurodegenerationNeuroinflammationNeuroprotectionRetina |
| spellingShingle | Anne Rombaut Rune Brautaset Pete A. Williams James R. Tribble Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma Molecular Brain Galectin-3 TD139 Neurodegeneration Neuroinflammation Neuroprotection Retina |
| title | Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma |
| title_full | Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma |
| title_fullStr | Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma |
| title_full_unstemmed | Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma |
| title_short | Intravitreal injection of the Galectin-3 inhibitor TD139 provides neuroprotection in a rat model of ocular hypertensive glaucoma |
| title_sort | intravitreal injection of the galectin 3 inhibitor td139 provides neuroprotection in a rat model of ocular hypertensive glaucoma |
| topic | Galectin-3 TD139 Neurodegeneration Neuroinflammation Neuroprotection Retina |
| url | https://doi.org/10.1186/s13041-024-01160-z |
| work_keys_str_mv | AT annerombaut intravitrealinjectionofthegalectin3inhibitortd139providesneuroprotectioninaratmodelofocularhypertensiveglaucoma AT runebrautaset intravitrealinjectionofthegalectin3inhibitortd139providesneuroprotectioninaratmodelofocularhypertensiveglaucoma AT peteawilliams intravitrealinjectionofthegalectin3inhibitortd139providesneuroprotectioninaratmodelofocularhypertensiveglaucoma AT jamesrtribble intravitrealinjectionofthegalectin3inhibitortd139providesneuroprotectioninaratmodelofocularhypertensiveglaucoma |